Institute Ramón y Cajal for Health Research.
CIBER-ONC, Carlos III Health Institute.
Am J Surg Pathol. 2020 May;44(5):649-656. doi: 10.1097/PAS.0000000000001432.
Mismatch repair deficiency (MMRD) is involved in the initiation of both hereditary and sporadic tumors. MMRD has been extensively studied in colorectal cancer and endometrial cancer, but not so in other tumors, such as ovarian carcinoma. We have determined the expression of mismatch repair proteins in a large cohort of 502 early-stage epithelial ovarian carcinoma entailing all the 5 main subtypes: high-grade serous carcinoma, endometrioid ovarian carcinoma (EOC), clear cell carcinoma (CCC), mucinous carcinoma, and low-grade serous carcinoma. We studied the association of MMRD with clinicopathologic and immunohistochemical features, including tumor-infiltrating lymphocytes in EOC, the histologic type in which MMRD is most frequent. In addition, MLH1 promoter methylation status and massive parallel sequencing were used to evaluate the proportion of sporadic and Lynch syndrome-associated tumors, and the most frequently mutated genes in MMRD EOCs. MMRD occurred only in endometriosis-associated histologic types, and it was much more frequent in EOC (18%) than in CCC (2%). The most frequent immunohistochemical pattern was loss of MLH1/PMS2, and in this group, 80% of the cases were sporadic and secondary to MLH1 promoter hypermethylation. The presence of somatic mutations in mismatch repair genes was the other mechanism of MMRD in sporadic tumors. In this series, the minimum estimated frequency of Lynch syndrome was 35% and it was due to germline mutations in MLH1, MSH2, and MSH6. ARID1A, PTEN, KTM2B, and PIK3CA were the most common mutated genes in this series. Interestingly, possible actionable mutations in ERRB2 were found in 5 tumors, but no TP53 mutations were detected. MMRD was associated with younger age and increased tumor-infiltrating lymphocytes. Universal screening in EOC and mixed EOC/CCC is recommended for the high frequency of MMRD detected; however, for CCC, additional clinical and pathologic criteria should be evaluated to help select cases for analysis.
错配修复缺陷 (MMRD) 参与了遗传性和散发性肿瘤的发生。MMRD 在结直肠癌和子宫内膜癌中得到了广泛研究,但在其他肿瘤中研究较少,如卵巢癌。我们在一个包含 502 例早期上皮性卵巢癌的大队列中确定了错配修复蛋白的表达情况,涵盖了所有 5 种主要亚型:高级别浆液性癌、子宫内膜样卵巢癌 (EOC)、透明细胞癌 (CCC)、黏液性癌和低级别浆液性癌。我们研究了 MMRD 与临床病理和免疫组织化学特征的关联,包括在 EOC 中肿瘤浸润淋巴细胞,这是 MMRD 最常见的组织学类型。此外,还使用 MLH1 启动子甲基化状态和大规模平行测序来评估散发性和林奇综合征相关肿瘤的比例,以及 MMRD EOC 中最常突变的基因。MMRD 仅发生在子宫内膜异位症相关的组织学类型中,在 EOC 中更为常见 (18%),而在 CCC 中则较少见 (2%)。最常见的免疫组织化学模式是 MLH1/PMS2 缺失,在这一组中,80%的病例是散发性的,继发于 MLH1 启动子超甲基化。在散发性肿瘤中,错配修复基因的体细胞突变是 MMRD 的另一种机制。在本系列中,林奇综合征的最小估计频率为 35%,是由于 MLH1、MSH2 和 MSH6 的种系突变引起的。在本系列中,ARID1A、PTEN、KTM2B 和 PIK3CA 是最常见的突变基因。有趣的是,在 5 例肿瘤中发现了可能的靶向治疗性 ERRB2 突变,但未检测到 TP53 突变。MMRD 与年龄较小和肿瘤浸润淋巴细胞增加有关。建议对 EOC 和混合 EOC/CCC 进行普遍筛查,以发现高频率的 MMRD;然而,对于 CCC,应评估其他临床和病理标准,以帮助选择进行分析的病例。